Top Page
Ascletis Pharma, Inc.
(1672)
Ascletis Pharma, Inc. (1672) vs. iShares MSCI Hong Kong ETF (EWH)
Ascletis Pharma, Inc. Business Overview & Revenue Model
Ascletis Pharma, Inc. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.28M | 56.60M | 54.09M | 76.88M | 35.00M |
| Gross Profit | 735.00K | 25.99M | -24.69M | 39.17M | -23.50M |
| EBITDA | -390.58M | -126.09M | -284.50M | -169.35M | -181.94M |
| Net Income | -300.94M | -144.72M | -366.71M | -202.14M | -262.05M |
Balance Sheet | |||||
| Total Assets | 2.12B | 2.49B | 2.66B | 2.83B | 3.07B |
| Cash, Cash Equivalents and Short-Term Investments | 1.95B | 2.30B | 2.48B | 2.50B | 2.71B |
| Total Debt | 7.63M | 8.42M | 4.24M | 2.75M | 1.59M |
| Total Liabilities | 158.41M | 148.94M | 117.16M | 100.89M | 85.42M |
| Stockholders Equity | 1.97B | 2.34B | 2.54B | 2.73B | 2.98B |
Cash Flow | |||||
| Free Cash Flow | -343.73M | -163.32M | -156.85M | -154.13M | -123.87M |
| Operating Cash Flow | -341.58M | -144.16M | -142.45M | -146.93M | -84.91M |
| Investing Cash Flow | 978.91M | 149.84M | -1.30B | -274.49M | 132.30M |
| Financing Cash Flow | -103.51M | -81.50M | -1.42M | -31.10M | -21.67M |
Ascletis Pharma, Inc. Technical Analysis
Ascletis Pharma, Inc. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$35.49B | 39.89 | 31.65% | ― | 4.23% | 47.71% | |
59 Neutral | HK$13.72B | ― | -51.40% | ― | 58.75% | -1310.16% | |
56 Neutral | HK$11.03B | ― | -13.97% | ― | -97.81% | -117.20% | |
53 Neutral | HK$14.02B | ― | -55.68% | ― | ― | -4.33% | |
52 Neutral | $7.46B | -0.04 | -63.82% | 2.49% | 16.43% | <0.01% | |
45 Neutral | HK$4.02B | ― | -69.97% | ― | ― | 3.30% | |
| ― | HK$9.52B | 107.31 | 4.95% | ― | ― | ― |
Ascletis Pharma, Inc. Corporate Events
Ascletis Pharma Inc. has announced a board meeting scheduled for August 15, 2025, to discuss and approve the interim results for the first half of the year and consider the recommendation of an interim dividend. This meeting is significant as it may impact the company’s financial strategy and shareholder returns, reflecting its operational progress and market positioning.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has completed dosing all participants in its U.S.-based clinical study evaluating the combination of its adipose-targeted, ultra-long-acting small molecule THR β agonist, ASC47, with semaglutide for obesity treatment. The study aims to assess the safety, tolerability, and preliminary efficacy of this combination, with topline data expected in the fourth quarter of 2025. The rapid enrollment of participants highlights the interest in new obesity treatments and the potential benefits of combination therapies, which could enhance Ascletis’s industry positioning and offer significant implications for stakeholders.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the dosing of the first participants in a U.S. 13-week Phase IIa study of its small molecule oral GLP-1 receptor agonist, ASC30, aimed at treating obesity and overweight individuals with weight-related comorbidities. This study is significant as it evaluates the efficacy, safety, and tolerability of ASC30, which has shown promising results in a previous Phase Ib study with a 6.5% placebo-adjusted mean body weight reduction. The successful development of ASC30 could enhance Ascletis’ position in the obesity treatment market, offering both oral and subcutaneous dosing options, with potential patent protection until 2044.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced that Conjupro Biotherapeutics, a subsidiary of CSPC Pharmaceutical Group, has filed a petition with the USPTO challenging the validity of one of Ascletis’ U.S. patents. This patent, crucial for the development of Ascletis’ drug candidate ASC30, is under review, and Ascletis is committed to defending its intellectual property rights. The company continues its operations unaffected while monitoring the situation closely.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has amended and adopted new terms of reference for its Nomination Committee, emphasizing the importance of diversity and transparency in board appointments. This move is aimed at enhancing the company’s governance structure, potentially impacting its operational efficiency and stakeholder trust.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the commencement of dosing in its U.S. Phase I clinical trial for ASC50, an oral small molecule IL-17 inhibitor aimed at treating psoriasis. This trial marks a significant step in Ascletis’ efforts to develop a potentially best-in-class treatment for psoriasis, with the study evaluating the drug’s safety, tolerability, and preliminary efficacy. The successful progression of this trial could enhance Ascletis’ position in the biopharmaceutical industry, potentially offering a new therapeutic option for psoriasis patients.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced that it will present poster presentations on its investigational drugs, ASC30 and ASC47, at the 85th Scientific Sessions of the American Diabetes Association in Chicago. ASC30 is a GLP-1R biased small molecule agonist with both oral and subcutaneous administration capabilities, protected by patents until 2044. ASC47 is a muscle-preserving weight loss drug candidate, currently in Phase I trials in combination with semaglutide, showing promising results in preclinical models. These developments highlight Ascletis’s commitment to advancing obesity treatment options, potentially strengthening its position in the pharmaceutical market.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced that its Phase III trial of Denifanstat (ASC40), a first-in-class, once-daily oral fatty acid synthase (FASN) inhibitor for acne, met all primary and secondary endpoints, demonstrating significant efficacy and a favorable safety profile. This breakthrough provides a potential new treatment for acne, showing superior effectiveness compared to existing FDA-approved treatments, and highlights Ascletis’s commitment to advancing dermatological therapies.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced a final judgment from the United States International Trade Commission regarding legal proceedings with Viking Therapeutics. The ruling imposes a seven-year prohibition on importing its drug candidates ASC41 and ASC43F into the U.S. and a joint liability payment of $567,059.85 due to procedural disputes. Despite the ruling, Ascletis states that the decision will not adversely affect its current operations as it is not pursuing these drug candidates. The company plans to seek further legal advice on appealing the judgment and remains committed to protecting its trade secrets.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced that the U.S. FDA has cleared its IND application for ASC50, an oral small molecule IL-17 inhibitor, for a Phase I trial targeting mild-to-moderate plaque psoriasis. ASC50 has shown promising preclinical results, including higher drug exposure and strong efficacy, positioning it as a potential best-in-class treatment. The Phase I trial is set to begin in the third quarter of 2025, marking a significant step in Ascletis’s development pipeline.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. held its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed, including the re-election of directors and the re-appointment of KPMG as auditors. The company granted mandates to the board to issue and repurchase shares, reflecting strong shareholder support and potentially enhancing its capital management strategy.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. has announced the dosing of the first participants in a U.S. clinical study combining their adipose-targeted small molecule THR β agonist, ASC47, with semaglutide for obesity treatment. This study aims to evaluate the safety and preliminary efficacy of ASC47, which has shown promising results in preclinical models by significantly enhancing weight loss with muscle preservation compared to semaglutide alone. The outcome of this study could potentially impact the company’s position in the obesity treatment market, with topline data expected by the fourth quarter of 2025.
The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.
Ascletis Pharma Inc. announced that it will present findings on ASC47, its adipose-targeted, muscle-preserving weight loss drug candidate, at the 32nd European Congress on Obesity. The presentations will showcase the drug’s potential in obesity treatment, highlighting significant weight loss and muscle preservation in preliminary studies. This development could enhance Ascletis’s position in the obesity treatment market, potentially impacting stakeholders by demonstrating the efficacy of ASC47 in clinical settings.
Ascletis Pharma Inc. has announced its 2025 Annual General Meeting, scheduled for May 22, 2025, in Hangzhou, China. The meeting will address several key business items, including the consideration of the company’s audited financial statements for 2024, the re-election of directors, and the re-appointment of KPMG as the auditor. Additionally, resolutions will be proposed to authorize the company’s board to manage share allotments and repurchases, potentially impacting the company’s capital structure and shareholder value.